IL254142B - Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent - Google Patents
Tredifitant for use in the treatment of a disease or medical condition that responds to TredifitentInfo
- Publication number
- IL254142B IL254142B IL254142A IL25414217A IL254142B IL 254142 B IL254142 B IL 254142B IL 254142 A IL254142 A IL 254142A IL 25414217 A IL25414217 A IL 25414217A IL 254142 B IL254142 B IL 254142B
- Authority
- IL
- Israel
- Prior art keywords
- tradipitant
- treatment
- condition
- responsive disease
- responsive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Eye Examination Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128472P | 2015-03-04 | 2015-03-04 | |
| US201562232644P | 2015-09-25 | 2015-09-25 | |
| PCT/US2016/021015 WO2016141341A1 (en) | 2015-03-04 | 2016-03-04 | Method of treatment with tradipitant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL254142A0 IL254142A0 (en) | 2017-10-31 |
| IL254142B true IL254142B (en) | 2022-05-01 |
Family
ID=55629110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254142A IL254142B (en) | 2015-03-04 | 2017-08-24 | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US10463655B2 (enExample) |
| EP (2) | EP3730140A1 (enExample) |
| JP (4) | JP6891385B2 (enExample) |
| KR (3) | KR102860817B1 (enExample) |
| CN (2) | CN113262221A (enExample) |
| AU (4) | AU2016226006B2 (enExample) |
| BR (1) | BR112017018620A2 (enExample) |
| CA (2) | CA2978736C (enExample) |
| CL (1) | CL2017002238A1 (enExample) |
| DK (1) | DK3265087T3 (enExample) |
| ES (1) | ES2824552T3 (enExample) |
| HR (1) | HRP20201627T1 (enExample) |
| HU (1) | HUE050944T2 (enExample) |
| IL (1) | IL254142B (enExample) |
| MX (2) | MX385788B (enExample) |
| PT (1) | PT3265087T (enExample) |
| RU (1) | RU2770050C2 (enExample) |
| WO (1) | WO2016141341A1 (enExample) |
| ZA (1) | ZA201706059B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CA3073998A1 (en) * | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| HRP20250615T1 (hr) | 2017-11-17 | 2025-07-18 | Vanda Pharmaceuticals Inc. | Tradipitant za upotrebu u liječenju gastropareze |
| US20210228555A1 (en) * | 2018-06-08 | 2021-07-29 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN111918701B (zh) * | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| WO2021173641A1 (en) | 2020-02-25 | 2021-09-02 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| JP7791832B2 (ja) * | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| JP2025542424A (ja) | 2022-12-21 | 2025-12-25 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる処置の方法 |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| GB9513972D0 (en) | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| DE60045564D1 (de) | 1999-02-24 | 2011-03-03 | Hoffmann La Roche | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| WO2003091227A1 (en) * | 2002-04-26 | 2003-11-06 | Eli Lilly And Company | Tachykinin receptor antagonists |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR100848407B1 (ko) | 2003-10-24 | 2008-07-28 | 일라이 릴리 앤드 캄파니 | ｛2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1ｈ-[1,2,3]트리아졸-4-일]-피리딘-3-일｝-(2-클로로페닐)-메탄온의 신규 결정질 형태 |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| US20090264388A1 (en) | 2006-02-22 | 2009-10-22 | Valorisation Recherche Hscm, Limited Partnership | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells |
| WO2008079600A1 (en) | 2006-12-20 | 2008-07-03 | Eli Lilly And Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| CN102573475B (zh) | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| HRP20140759T1 (hr) | 2009-11-18 | 2014-10-24 | Helsinn Healthcare S.A. | Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| WO2014093907A1 (en) | 2012-12-13 | 2014-06-19 | A.P. Pharma, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| US8906951B1 (en) * | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| HK1223820A1 (zh) * | 2013-06-24 | 2017-08-11 | Menlo Therapeutics Inc. | Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途 |
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2016195723A1 (en) | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| MX378145B (es) | 2015-11-30 | 2025-03-10 | Anacor Pharmaceuticals Inc | Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias |
| CA3009325A1 (en) | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
| CA3073998A1 (en) * | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| HRP20250615T1 (hr) * | 2017-11-17 | 2025-07-18 | Vanda Pharmaceuticals Inc. | Tradipitant za upotrebu u liječenju gastropareze |
| US20210228555A1 (en) * | 2018-06-08 | 2021-07-29 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| CN111918701B (zh) * | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| WO2020117811A1 (en) * | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
-
2016
- 2016-03-04 WO PCT/US2016/021015 patent/WO2016141341A1/en not_active Ceased
- 2016-03-04 CA CA2978736A patent/CA2978736C/en active Active
- 2016-03-04 PT PT167119312T patent/PT3265087T/pt unknown
- 2016-03-04 JP JP2017546704A patent/JP6891385B2/ja active Active
- 2016-03-04 MX MX2017011279A patent/MX385788B/es unknown
- 2016-03-04 HU HUE16711931A patent/HUE050944T2/hu unknown
- 2016-03-04 US US15/553,394 patent/US10463655B2/en active Active
- 2016-03-04 EP EP20180523.1A patent/EP3730140A1/en active Pending
- 2016-03-04 CN CN202110527432.8A patent/CN113262221A/zh active Pending
- 2016-03-04 CN CN201680013797.6A patent/CN107427502B/zh active Active
- 2016-03-04 CA CA3213864A patent/CA3213864C/en active Active
- 2016-03-04 KR KR1020237043041A patent/KR102860817B1/ko active Active
- 2016-03-04 RU RU2017134443A patent/RU2770050C2/ru active
- 2016-03-04 HR HRP20201627TT patent/HRP20201627T1/hr unknown
- 2016-03-04 AU AU2016226006A patent/AU2016226006B2/en active Active
- 2016-03-04 KR KR1020257030197A patent/KR20250136946A/ko active Pending
- 2016-03-04 EP EP16711931.2A patent/EP3265087B1/en active Active
- 2016-03-04 DK DK16711931.2T patent/DK3265087T3/da active
- 2016-03-04 BR BR112017018620-9A patent/BR112017018620A2/pt not_active Application Discontinuation
- 2016-03-04 KR KR1020177026588A patent/KR20170122777A/ko not_active Ceased
- 2016-03-04 ES ES16711931T patent/ES2824552T3/es active Active
-
2017
- 2017-08-24 IL IL254142A patent/IL254142B/en unknown
- 2017-09-04 MX MX2021010460A patent/MX2021010460A/es unknown
- 2017-09-04 CL CL2017002238A patent/CL2017002238A1/es unknown
- 2017-09-06 ZA ZA2017/06059A patent/ZA201706059B/en unknown
-
2019
- 2019-06-04 US US16/430,516 patent/US20190290626A1/en not_active Abandoned
- 2019-06-04 US US16/430,514 patent/US10772880B2/en active Active
-
2020
- 2020-07-31 US US16/944,596 patent/US11324735B2/en active Active
-
2021
- 2021-01-28 JP JP2021012356A patent/JP2021073258A/ja active Pending
- 2021-05-10 AU AU2021202956A patent/AU2021202956B2/en active Active
-
2022
- 2022-04-06 US US17/714,998 patent/US12318375B2/en active Active
-
2023
- 2023-01-18 JP JP2023006082A patent/JP2023052486A/ja active Pending
- 2023-09-21 AU AU2023233141A patent/AU2023233141B2/en active Active
-
2024
- 2024-04-09 JP JP2024062811A patent/JP2024074963A/ja not_active Withdrawn
-
2025
- 2025-03-12 US US19/078,214 patent/US20250205213A1/en active Pending
- 2025-08-04 AU AU2025210905A patent/AU2025210905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256175A (en) | Using exosomes to treat the disease | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| PT3334422T (pt) | Utilização de ácido canabidiólico no tratamento de epilepsia | |
| GB201510664D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL247072A0 (en) | Medical use | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| GB201502137D0 (en) | Treatment | |
| GB201608885D0 (en) | Treatment | |
| IL250990A0 (en) | Materials for human care | |
| IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| GB2538923B (en) | A therapeutic agent for use in the treatment of infections | |
| PT3160464T (pt) | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento | |
| GB201502412D0 (en) | Therapeutic use | |
| GB201608797D0 (en) | Therapeutic use | |
| GB201508841D0 (en) | Treatment | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201503008D0 (en) | Treatment | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment | |
| GB2555225B (en) | Hydrocarbon-contamination treatment unit | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| IL247732A0 (en) | Perinase inhibitory peptides and their use in the treatment of clinical pathologies | |
| GB201609683D0 (en) | Treatment |